Press Releases Archives - Page 30 of 103 - Lupin

BSE 2350.25 NSE 2345.60

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2350.25 NSE 2345.60

Lupin Launches Sildenafil for Oral Suspension in the United States

September 29, 2022

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

September 22, 2022

Lupin Receives Health Canada Approval for Rymti® (biosimilar Etanercept)

September 13, 2022

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

September 9, 2022

Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines

September 7, 2022

Lupin Receives Tentative Approval from U.S. FDA for Dasatinib Tablets

August 29, 2022

Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States

August 26, 2022

Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD

August 26, 2022

Lupin and I’rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan

August 25, 2022

Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution

August 24, 2022

1 2 … 29 30 31 … 102 103

Search

Hit enter to search or ESC to close